Whitehawk Therapeutics
WHWK
20 hedge funds and large institutions have $35.2M invested in Whitehawk Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
33% more funds holding
Funds holding: 15 → 20 (+5)
9% less capital inflows, than outflows
Capital inflows: $4.78M | Capital outflows: $5.26M
1.45% less ownership
Funds ownership: 29.51% → 28.06% (-1.4%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.03M |
| 2 |
Goldman Sachs
New York
|
+$406K |
| 3 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$106K |
| 4 |
Jane Street
New York
|
+$97K |
| 5 |
Raymond James & Associates
St Petersburg,
Florida
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.31M |
| 2 |
Nexthera Capital
New York
|
-$1.24M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.17M |
| 4 |
Millennium Management
New York
|
-$934K |
| 5 |
CVI Holdings
Wilmington,
Delaware
|
-$601K |
WHWK Hedge Fund Activity: Q3 2018 in Review
20 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2018, worth a combined $35.2M — down 26% from $47.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new WHWK positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $4.03M. The largest seller was Granite Point Capital Management, cutting an estimated $1.31M.
- 20 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2018, up from 15 in Q2 2018.
- Funds reported $35.2M of Whitehawk Therapeutics stock for Q3 2018, down 26% quarter-over-quarter.
- 8 funds opened new Whitehawk Therapeutics positions in Q3 2018 and 3 closed out, a net change of +5 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2018 was Vanguard Group, an estimated $4.03M added.
- The largest Whitehawk Therapeutics seller in Q3 2018 was Granite Point Capital Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q3 2018.